Induction of potent antitumor immunity by in situ targeting of intratumoral DCs
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Nonstandard abbreviations used: antigen (Ag); bone marrow (BM); CG-rich motif (CpG); complete medium (CM); control oligonucleotide (ODN-CTR); effector/target (E/T); Fms-like thyrosine kinase 3 ligand (Flt3L); Langerhans cell (LC); macrophage inflammatory protein-3α (MIP-3α); mean fluorescence intensity (MFI); T cell receptor (TCR).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A preclinical murine melanoma model showed increased migration of DCs in CCL20‐positive tumor cells, indicating the role of CCL20 in attracting DCs to the tumor site [368].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [368]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Immunobiology of Dendritic Cells
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.-J., Pulendran, B., & Palucka, K. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.767 · Cited by 6,634
T cell receptor antagonist peptides induce positive selection
Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., & Carbone, F. R. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 2,858
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
REGULATION OF IMMUNE RESPONSES BY TGF-β
Letterio, J. J., & Roberts, A. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.137 · Cited by 1,890
Dieu, M.-C., Vanbervliet, B., Vicari, A., Bridon, J.-M., Oldham, E., Aït-Yahia, S., Brière, F., Zlotnik, A., Lebecque, S., & Caux, C. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.373 · Cited by 1,425
Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C., & Bhardwaj, N. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.2.233 · Cited by 1,359
Induction of tolerance by IL-10-treated dendritic cells
Steinbrink, K., Wölfl, M., Jonuleit, H., Knop, J., & Enk, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.10.4772 · Cited by 1,246
Maraskovsky, E., Brasel, K., Teepe, M., Roux, E. R., Lyman, S. D., Shortman, K., & McKenna, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.5.1953 · Cited by 1,115
Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Martin Kast, W., Deleo, A. B., et al. (1995) · Nature Medicine · doi:10.1038/nm1295-1297 · Cited by 1,074
Research works printed but not linked: 3
- Gabrilovich, D.I., Corak, J., Ciernik, I.F., Kavanaugh, D., and Carbone, D.P. 1997. Decreased antigen pre- sentation by dendritic cells in patients with breast cancer. Clin. Cancer Res. 3:483-490.
- Nestle, F.O., Burg, G., Fah, J., Wrone-Smith, T., and Nickoloff, B.J. 1997. Human sunlight-induced basal- cell-carcinoma-associated dendritic cells are deficient in T cell co-stimulatory molecules and are impaired as antigen-presenting cells. Am. J. Pathol. 150:641-651.
- Chen, K., et al. 1997. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 57:3511-3516.
Cited by
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N. P., Overwijk, W. W., & Dong, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.014 · Cited by 800
Key chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance
Huang, B., Zhao, J., Li, H., He, K.-L., Chen, Y., Mayer, L., Unkeless, J. C., & Xiong, H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0784 · Cited by 542
Twelve immunotherapy drugs that could cure cancers
‘Mac’ Cheever, M. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00604.x · Cited by 341
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities
Sedighi, M., Zahedi Bialvaei, A., Hamblin, M. R., Ohadi, E., Asadi, A., Halajzadeh, M., Lohrasbi, V., Mohammadzadeh, N., Amiriani, T., Krutova, M., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2148 · Cited by 308
The role of dendritic cells in cancer and anti-tumor immunity
Marciscano, A. E., & Anandasabapathy, N. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101481 · Cited by 298
den Brok, M. H. M. G. M., Sutmuller, R. P. M., Nierkens, S., Bennink, E. J., Frielink, C., Toonen, L. W. J., Boerman, O. C., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603341 · Cited by 296
Challenges in developing personalized neoantigen cancer vaccines
Katsikis, P. D., Ishii, K. J., & Schliehe, C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00937-y · Cited by 258
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors
Thompson, E. D., Enriquez, H. L., Fu, Y.-X., & Engelhard, V. H. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092454 · Cited by 249
Neuropilin 1: function and therapeutic potential in cancer
Chaudhary, B., Khaled, Y. S., Ammori, B. J., & Elkord, E. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1500-0 · Cited by 233
Negative Regulation of TLR-Signaling Pathways by Activating Transcription Factor-3
Whitmore, M. M., Iparraguirre, A., Kubelka, L., Weninger, W., Hai, T., & Williams, B. R. G. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.3622 · Cited by 214
Dendritic-cell-based therapeutic vaccination against cancer
Nestle, F. O., Farkas, A., & Conrad, C. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.02.003 · Cited by 199
Aspord, C., Leccia, M.-T., Charles, J., & Plumas, J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0114-t · Cited by 187
In situ vaccination: Cancer immunotherapy both personalized and off‐the‐shelf
Hammerich, L., Binder, A., & Brody, J. D. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.016 · Cited by 187
Chemokines in colon cancer progression
Jia, S., Han, Y.-B., Yang, R., & Yang, Z. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.007 · Cited by 184
Cancer Immunotherapy Based on Killing of Salmonella -Infected Tumor Cells
Avogadri, F., Martinoli, C., Petrovska, L., Chiodoni, C., Transidico, P., Bronte, V., Longhi, R., Colombo, M. P., Dougan, G., & Rescigno, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3002 · Cited by 181
den Brok, M. H. M. G. M., Sutmuller, R. P. M., Nierkens, S., Bennink, E. J., Toonen, L. W. J., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0206 · Cited by 176
Kim, T. H., Jin, H., Kim, H. W., Cho, M.-H., & Cho, C. S. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0540 · Cited by 164
Cross-priming in cancer immunology and immunotherapy
Luri‐Rey, C., Teijeira, Á., Wculek, S. K., de Andrea, C. E., Herrero, C., López‐Janeiro, Á., Rodriguez-Ruiz, M. E., Heras‐Murillo, I., Aggelakopoulou, M., Berraondo, P., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00785-5 · Cited by 165
Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity
Savage, T. M., Vincent, R. L., Rae, S. S., Huang, L. H., Ahn, A., Pu, K., Li, F., de los Santos-Alexis, K., Coker, C., Danino, T., et al. (2023) · Science Advances · doi:10.1126/sciadv.adc9436 · Cited by 161
The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy
Cueto, F. J., & Sancho, D. (2021) · Cancers · doi:10.3390/cancers13071525 · Cited by 148
The Tumor Microenvironment: A Pitch for Multiple Players
Schiavoni, G., Gabriele, L., & Mattei, F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00090 · Cited by 147
Van Lint, S., Renmans, D., Broos, K., Goethals, L., Maenhout, S., Benteyn, D., Goyvaerts, C., Du Four, S., Van der Jeught, K., Bialkowski, L., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0163 · Cited by 130
Hori, Y., Winans, A. M., & Irvine, D. J. (2009) · Acta Biomaterialia · doi:10.1016/j.actbio.2008.11.019 · Cited by 127
Stachowiak, A. N., & Irvine, D. J. (2008) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31661 · Cited by 122
Migration of dendritic cell based cancer vaccines: in vivo veritas?
Adema, G. J., de Vries, I. J. M., Punt, C. J., & Figdor, C. G. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.01.004 · Cited by 134
Salem, M. L., Díaz-Montero, C. M., Al-Khami, A. A., El-Naggar, S. A., Naga, O., Montero, A. J., Khafagy, A., & Cole, D. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801829 · Cited by 115
Kim, R., Emi, M., & Tanabe, K. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.9.2101 · Cited by 125
Dendritic cell vaccines in melanoma: From promise to proof?
Lesterhuis, W. J., Aarntzen, E. H. J. G., de Vries, I. J. M., Schuurhuis, D. H., Figdor, C. G., Adema, G. J., & Punt, C. J. A. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.12.007 · Cited by 124
Tumor-induced modulation of dendritic cell function
Gottfried, E., Kreutz, M. P., & Mackensen, A. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.10.008 · Cited by 127
Bos, J. D., & Luiten, R. M. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-78574-5_5 · Cited by 118
DNA vaccination against tumors
Prud’homme, G. J. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.669 · Cited by 117
In Situ Vaccination for the Treatment of Cancer
Hammerich, L., Bhardwaj, N., Kohrt, H. E., & Brody, J. D. (2016) · Immunotherapy · doi:10.2217/imt.15.120 · Cited by 105
Berg, M., Wingender, G., Djandji, D., Hegenbarth, S., Momburg, F., Hämmerling, G., Limmer, A., & Knolle, P. (2006) · European Journal of Immunology · doi:10.1002/eji.200636033 · Cited by 99
Nierkens, S., den Brok, M. H., Roelofsen, T., Wagenaars, J. A. L., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008368 · Cited by 108
Hu, J., Yuan, X., Belladonna, M. L., Ong, J. M., Wachsmann‐Hogiu, S., Farkas, D. L., Black, K. L., & Yu, J. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3448 · Cited by 106
Directed cell migration via chemoattractants released from degradable microspheres
Zhao, X., Jain, S., Larman, H. B., Gonzalez, S., & Irvine, D. J. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.12.003 · Cited by 106
Brave Little World: Spheroids as an in vitro Model to Study Tumor-Immune-Cell Interactions
Gottfried, E., Kunz-Schughart, L. A., Andreesen, R., & Kreutz, M. (2006) · Cell Cycle · doi:10.4161/cc.5.7.2624 · Cited by 91
Saji, H., Song, W., Furumoto, K., Kato, H., & Engleman, E. G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1986 · Cited by 98
Self-citationThe Janus face of dendritic cells in cancer
Chaput, N., Conforti, R., Viaud, S., Spatz, A., & Zitvogel, L. (2008) · Oncogene · doi:10.1038/onc.2008.270 · Cited by 96
Lapteva, N., Aldrich, M. B., Weksberg, D. C., Rollins, L. A., Goltsova, T., Chen, S. Y., & Huang, X. F. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318193d31e · Cited by 92
Jurk, M., & Vollmer, J. (2007) · BioDrugs · doi:10.2165/00063030-200721060-00006 · Cited by 89
Immunostimulatory combinations: designing the next generation of vaccine adjuvants
Kornbluth, R. S., & Stone, G. W. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306147 · Cited by 78
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 87
Aspord, C., Tramcourt, L., Leloup, C., Molens, J., Leccia, M. ‐., Charles, J., & Plumas, J. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.194 · Cited by 86
Samaniego, R., Gutiérrez‐González, A., Gutiérrez‐Seijo, A., Sánchez‐Gregorio, S., García‐Giménez, J., Mercader, E., Márquez‐Rodas, I., Avilés, J. A., Relloso, M., & Sánchez‐Mateos, P. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0198 · Cited by 86
Dendritic Cells in Cancer Immunotherapy
Vulink, A. J. E., Radford, K. J., Melief, C. J. M., & Hart, D. N. J. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(07)99006-5 · Cited by 85
Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant
Overwijk, W. W., de Visser, K. E., Tirion, F. H., de Jong, L. A., Pols, T. W. H., van der Velden, Y. U., van den Boorn, J. G., Keller, A. M., Buurman, W. A., Theoret, M. R., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5213 · Cited by 85
CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans
Haining, W. N., DAVIES, J. K., Kanzler, H., Drury, L., Brenn, T., Evans, J., Angelosanto, J., Rivoli, S., Russell, K. E. R., George, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0526 · Cited by 82
Domingos‐Pereira, S., Warpelin‐Decrausaz, L., Derré, L., Bobst, M., Romero, P. J., Schiller, J. T., Jichlinski, P., & Nardelli‐Haefliger, D. (2012) · Mucosal Immunology · doi:10.1038/mi.2012.83 · Cited by 79
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model
King, G. D., Muhammad, A. K. M. G., Curtin, J. F., Barcia, C., Puntel, M., Liu, C., Honig, S. B., Candolfi, M., Mondkar, S., Lowenstein, P. R., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-045 · Cited by 79
Advances in engineering local drug delivery systems for cancer immunotherapy
Abdou, P., Wang, Z., Chen, Q., Chan, A., Zhou, D. R., Gunadhi, V., & Gu, Z. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1632 · Cited by 78
Iida, N., Nakamoto, Y., Baba, T., Nakagawa, H., Mizukoshi, E., Naito, M., Mukaida, N., & Kaneko, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0096 · Cited by 76
Nie, Y., He, J., Shirota, H., Trivett, A. L., Yang, D., Klinman, D. M., Oppenheim, J. J., & Chen, X. (2018) · Science Signaling · doi:10.1126/scisignal.aan0790 · Cited by 76
Galili, U., Wigglesworth, K., & Abdel-Motal, U. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4676 · Cited by 71
The role of bacterial toxins and spores in cancer therapy
Weerakkody, L. R., & Witharana, C. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116839 · Cited by 75
Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy
Hori, Y., Stern, P. J., Hynes, R. O., & Irvine, D. J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.08.037 · Cited by 70
Earl, T. M., Nicoud, I. B., Pierce, J. M., Wright, J. P., Majoras, N. E., Rubin, J. E., Pierre, K. P., Gorden, D. L., & Chari, R. S. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0325-8 · Cited by 72
Edukulla, R., Woller, N., Mundt, B., Knocke, S., Gürlevik, E., Saborowski, M., Malek, N. P., Manns, M. P., Wirth, T. C., Kühnel, F., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1160 · Cited by 69
A Novel Cancer Vaccine Strategy Based on HLA-A*0201 Matched Allogeneic Plasmacytoid Dendritic Cells
Aspord, C., Charles, J., Leccia, M. ‐., Laurin, D., Richard, M., Chaperot, L., & Plumas, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010458 · Cited by 68
Intratumoral Expression of Mature Human Neutrophil Peptide-1 Mediates Antitumor Immunity in Mice
Wang, Y., Li, D., Shi, H., Wen, Y., Yang, L., Xu, N., Chen, X., Chen, X., Chen, P., Li, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0484 · Cited by 68
Breaking tolerance in cancer immunotherapy: time to ACT
Overwijk, W. W. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.01.011 · Cited by 68
Nierkens, S., den Brok, M. H., Sutmuller, R. P. M., Grauer, O. M., Bennink, E. J., Morgan, M. E., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6023 · Cited by 63
Dewin, D., Catusse, J., & Gompels, U. A. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.544 · Cited by 63
Combination of radiofrequency ablation and immunotherapy
Fagnoni, F. F. (2007) · Frontiers in bioscience · doi:10.2741/2686 · Cited by 63
Immune system versus tumor: shifting the balance in favor of DCs and effective immunity
Kaufman, H. L., & Disis, M. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21148 · Cited by 62
Guo, J., Zhu, J., Sheng, X., Wang, X., Qu, L., Yan, H., Liu, Y., Zhang, H., Huo, L., Zhang, S., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22551 · Cited by 60
Attraction and Activation of Dendritic Cells at the Site of Tumor Elicits Potent Antitumor Immunity
Lapteva, N., Aldrich, M. B., Rollins, L. A., Ren, W., Goltsova, T., Chen, S.-Y., & Huang, X. F. (2009) · Molecular Therapy · doi:10.1038/mt.2009.111 · Cited by 58
Song, R., Liu, S., & Leong, K. W. (2007) · Molecular Therapy · doi:10.1038/mt.sj.6300129 · Cited by 57
Dendritic cells: tools and targets for antitumor vaccination
den Brok, M. H., Nierkens, S., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.5.699 · Cited by 58
Langerhans cells and their role in oral mucosal diseases
Upadhyay, R. B., Jaitley, S., Shekhar, R., Agrawal, P. B., & Upadhyay, J. (2013) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.118923 · Cited by 57
Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy
Kigasawa, K., Kajimoto, K., Nakamura, T., Hama, S., Kanamura, K., Harashima, H., & Kogure, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.018 · Cited by 57
RETRACTED: Immunosuppressive networks in the tumour environment and their effect in dendritic cells
Bennaceur, K., Chapman, J. A., Touraine, J. L., & Portoukalian, J. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.07.001 · Cited by 55
RetractedCCL20 promotes lung adenocarcinoma progression by driving epithelial-mesenchymal transition
Fan, T. T., Li, S., Xiao, C., Tian, H., Zheng, Y., Liu, Y., Li, C., & He, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73275 · Cited by 53
Mesothelioma Tumor Cells Modulate Dendritic Cell Lipid Content, Phenotype and Function
Gardner, J. K., Mamotte, C. D. S., Patel, P., Yeoh, T. L., Jackaman, C., & Nelson, D. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123563 · Cited by 50
HLA-A*0201 Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients
Aspord, C., Leccia, M. ‐., Salameire, D., Laurin, D., Chaperot, L., Charles, J., & Plumas, J. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.152 · Cited by 51
Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic
Breitbach, C. J., Parato, K. A., Burke, J., Hwang, T.-H., Bell, J. C., & Kirn, D. H. (2015) · Current Opinion in Virology · doi:10.1016/j.coviro.2015.03.016 · Cited by 50
Plasmacytoid dendritic cell role in cutaneous malignancies
Saadeh, D., Kurban, M., & Abbas, O. M. (2016) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2016.05.008 · Cited by 48
Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
Prokopi, N., Tripp, C. H., Tummers, B., Hornsteiner, F., Spoeck, S., Crawford, J. C., Clements, D. R., Efremova, M., Hutter, K., Bellmann, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000832 · Cited by 48
Okano, F., Mérad, M., Furumoto, K., & Engleman, E. G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2645 · Cited by 48
Self-citationEGFR/Ras-induced CCL20 production modulates the tumour microenvironment
Hippe, A., Braun, S. A., Oláh, P., Gerber, P. A., Schorr, A., Seeliger, S., Holtz, S., Jannasch, K., Pivarcsi, A., Buhren, B. A., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0943-2 · Cited by 47
Characterisation of dendritic cell subsets in lung cancer micro-environments
Bergeron, A., Hage, F. E., Kambouchner, M., Lecossier, D., & Tazi, A. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00114205 · Cited by 46
Immunotherapy and immunoescape in colorectal cancer
Mazzolini, G. D., Murillo, O., Atorrasagasti, C., Dubrot, J., Tirapu, I., Rizzo, M., Arina, A., Alfaro, C., Azpilicueta, A., Berasain, C., et al. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i44.5822 · Cited by 45
Xu, F., He, P., Zeng, C., Li, Y., Das, S. K., Li, B., Yang, H., & Du, Y. (2020) · Oncology Letters · doi:10.3892/ol.2020.12371 · Cited by 44
Betting, D. J., Yamada, R. E., Kafi, K., SAID, J. W., van Rooijen, N., & Timmerman, J. M. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ab23f1 · Cited by 42
Attenuated Bacteria as Effectors in Cancer Immunotherapy
al-Ramadi, B. K., Fernández-Cabezudo, M. J., Elhasasna, H., Al‐Salam, S., Attoub, S., Xu, D., & Chouaïb, S. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1414.036 · Cited by 40
Verma, V., Kim, Y., Lee, M.-C., Lee, J., Cho, S., Park, I., Min, J. J., Lee, J. J., Lee, S. E., & Rhee, J. H. (2016) · Oncotarget · doi:10.18632/oncotarget.9529 · Cited by 39
Abdel‐Motal, U. M., Wigglesworth, K., & Galili, U. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0662-2 · Cited by 38
Toll-Like Receptor 4 Signaling Promotes the Migration of Human Melanoma Cells
Takazawa, Y., Kiniwa, Y., Ogawa, E., Uchiyama, A., Ashida, A., Uhara, H., Goto, Y., & Okuyama, R. (2014) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.234.57 · Cited by 36
Chemokine–Chemokine Receptors in Cancer Immunotherapy
Stewart, T. J., & Smyth, M. J. (2008) · Immunotherapy · doi:10.2217/1750743x.1.1.109 · Cited by 36
Chavan, R., Marfatia, K. A., An, I., Garber, D. A., & Feinberg, M. B. (2006) · Journal of Virology · doi:10.1128/jvi.02748-05 · Cited by 35
Gene Therapy with Beta-Defensin 2 Induces Antitumor Immunity and Enhances Local Antitumor Effects
Li, D., Wang, W., Shi, H., Fu, Y., Chen, X., Chen, X., Liu, Y., Kan, B., & Wang, Y. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.161 · Cited by 34
Outlining novel cellular adjuvant products for therapeutic vaccines against cancer
Nitcheu-Tefit, J., & Serra, V. A. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.84 · Cited by 34
Salter, R. D., & Shurin, M. R. (2009) · Springer eBooks · doi:10.1007/978-0-387-88611-4 · Cited by 33
IFN-γ Negatively Regulates CpG-Induced IL-10 in Bone Marrow-Derived Dendritic Cells
Flores, R. R., Diggs, K. A., Tait, L. M., & Morel, P. A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.211 · Cited by 33
Berhanu, A., Huang, J., Alber, S. M., Watkins, S. C., & Storkus, W. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2384 · Cited by 33
Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models
Klarquist, J. S., & Janssen, E. M. (2012) · OncoImmunology · doi:10.4161/onci.22660 · Cited by 32
Metadata
- Authors
- Furumoto, K., Soares, L., Engleman, E. G., & Merad, M.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Engleman, Edgar G.
- ORCID
- Engleman, Edgar G.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-03-01
- Volume
- 113
- Issue
- 5
- Pages
- 774-783
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4238827986
- Cited by
- 180
- References
- 43
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 8 · 2023: 7 · 2022: 3 · 2021: 6 · 2020: 5 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 6 · 2015: 6 · 2014: 4 · 2013: 6 · 2012: 6
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- antitumor immunity, dendritic cells, cancer immunotherapy, Langerhans cells, macrophage inflammatory protein-3α, Flt3 ligand, CpG oligodeoxynucleotides, T cell activation, tumor-associated macrophages
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.